Rifapentine
- Generic Name
- Rifapentine
- Brand Names
- Priftin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H64N4O12
- CAS Number
- 61379-65-5
- Unique Ingredient Identifier
- XJM390A33U
- Background
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
- Indication
For the treatment of pulmonary tuberculosis.
- Associated Conditions
- Active Tuberculosis, Late phase Tuberculosis
- Associated Therapies
- -
Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT06281834
Shortened Regimen for Drug-susceptible TB in Children
- Conditions
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 860
- Registration Number
- NCT06253715
- Locations
- 🇮🇳
Indian Council of Medical Research - National Institute for Research in Tuberculosis, Chennai, India
🇮🇳Dr. D.Y. Patil Medical College, Hospital and Research Center, Pimpri, Pune, India
🇮🇩Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-02-20
- Target Recruit Count
- 350
- Registration Number
- NCT06191692
- Locations
- 🇻🇳
Ha Noi Lung Hospital, Hà Nội, Vietnam
🇻🇳Vietnam National Lung Hospital, Hà Nội, Ha Noi, Vietnam
Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment
- Conditions
- Interventions
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 620
- Registration Number
- NCT05454345
Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV
- Conditions
- Interventions
- First Posted Date
- 2021-11-16
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- The Aurum Institute NPC
- Target Recruit Count
- 252
- Registration Number
- NCT05122026
- Locations
- 🇿🇦
The Aurum Institute: Tembisa Clinical Research Centre, Tembisa, Gauteng, South Africa
🇿🇦Peri Natal HIV Research Unit - Klerksdorp Tshepong Hospital, Klerksdorp, North-West, South Africa
🇿🇦FAMily Centre for Research with Ubuntu (FAMCRU), Cape Town, South Africa
Tuberculosis Clinical Trials Consortium Study 35
- First Posted Date
- 2018-11-05
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 72
- Registration Number
- NCT03730181
- Locations
- 🇿🇦
Desmond Tutu TB Center, University of Stellenbosch, Stellenbosch, South Africa
Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA)
- Conditions
- Interventions
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2024-08-13
- Target Recruit Count
- 51
- Registration Number
- NCT03510468
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- University College, London
- Target Recruit Count
- 675
- Registration Number
- NCT03474198
- Locations
- 🇮🇩
Saiful Anwar Hospital, Malang, Indonesia
🇺🇬Joint Clinical Research Centre, Mbarara, Uganda
🇺🇬Infectious Diseases Institute, Kampala, Uganda
Treatment of Latent Tuberculosis in Socially Marginalised Citizens
- First Posted Date
- 2017-08-30
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Aarhus University Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT03266991
- Locations
- 🇩🇰
Dept of Pulmonary Medicine, Esbjerg, Denmark
Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings
- Conditions
- Interventions
- First Posted Date
- 2017-03-24
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Yale University
- Target Recruit Count
- 1702
- Registration Number
- NCT03089983
- Locations
- 🇲🇾
Kajang Prison, Kajang, Selangor, Malaysia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.